On June 9th, PolyPid Ltd.* announced landmark topline results from its pivotal SHIELD II Phase 3 trial, demonstrating that D-PLEX100 achieved statistically significant reductions across all primary and secondary endpoints in preventing surgical site infections (SSIs). The study's compelling efficacy profile—including a 58% reduction in SSIs, 38% reduction in the composite primary endpoint, and 62% reduction in severe wound infections—validates the company's innovative PLEX technology platform and positions ...